Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Takeda Pharmaceutical Company Limited (TAK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
14.09+0.05 (+0.36%)
At close: 04:00PM EDT
13.85 -0.25 (-1.74%)
After hours: 07:23PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.04
Open13.92
Bid13.51 x 3200
Ask14.25 x 2200
Day's Range13.91 - 14.11
52 Week Range13.05 - 17.31
Volume2,174,812
Avg. Volume2,682,083
Market Cap43.893B
Beta (5Y Monthly)1.00
PE Ratio (TTM)10.82
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.80 (5.60%)
Ex-Dividend DateSep 29, 2021
1y Target EstN/A
  • Benzinga

    Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years

    Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022. The data demonstrated positive results of Takhzyro (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult and adolescent patients. HAE attacks, which can involve serious and severely debilitating swelling in the

  • Bloomberg

    Takeda Is ‘Now In a Good Phase’ for Growth, CEO Weber Says

    (Bloomberg) -- Takeda Pharmaceutical Co.’s shares might be trading at about half of their level before the $62 billion acquisition of Shire in 2018, but the drug pipeline and cash management are helping to change the market’s perception of the company’s long-term value, Chief Executive Officer Christophe Weber said.Most Read from BloombergTrump’s Final Scene Didn’t Go According to ScriptDemocrats Weigh Paring Biden Tax Hike to Win Over ManchinVenice Plans to Start Weeding Out Cheap TouristsFauci

  • American City Business Journals

    Takeda leases future Kendall Square building

    The agreement to take 600,000 square feet on Third Street is part of an effort to consolidate more of its operations in Kendall, the drug giant said Wednesday.

Advertisement
Advertisement